Related Experiment Video

Updated: Jun 7, 2026

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections
16:56

Sublingual Immunotherapy as an Alternative to Induce Protection Against Acute Respiratory Infections

Published on: August 30, 2014

[Cost-effectiveness of universal pneumococcal vaccination in Uruguay]

Gustavo Giachetto Larraz1, Héctor Telechea Ortiz, Noelia Speranza Mourine

  • 1Departamento de Pediatría, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay. ggiachet@gmail.com

Revista Panamericana De Salud Publica = Pan American Journal of Public Health
|October 22, 2010
PubMed

Insights

The universal vaccination program using heptavalent pneumococcal conjugate vaccine (PCV7) in Uruguay is highly cost-effective. This program significantly prevents deaths and illness, making it recommendable for similar countries.

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics

Context:

  • Pneumococcal disease poses a significant health burden on children under 5.
  • Uruguay's healthcare system sought to evaluate the economic viability of a universal vaccination program.
  • The heptavalent pneumococcal conjugate vaccine (PCV7) was considered for widespread implementation.

Purpose:

  • To assess the cost-effectiveness of a universal vaccination program with PCV7 in Uruguayan children under 5.
  • To determine the incremental cost per life year gained (LYG) and quality-adjusted life year (QALY).
  • To provide evidence for policy decisions regarding pneumococcal vaccination.

Summary:

  • A Markov model simulated 48,000 children from birth to age 76, using a 3-dose PCV7 regimen with 5-year protection.
  • Vaccine efficacy and effectiveness were adapted from US studies to Uruguay's serotype prevalence.
  • Results indicated an incremental cost of $7334.60/LYG and $4655.80/QALY, preventing substantial disease and deaths.

Impact:

  • The PCV7 universal vaccination program in Uruguay demonstrates high cost-effectiveness.
  • The program is recommended for countries facing similar pneumococcal disease burdens and serotype distributions.
  • Findings support the integration of PCV7 into national immunization schedules for improved child health outcomes.
Abstract

More Related Videos

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis06:26

Micro-Colony Forming Unit Assay for Efficacy Evaluation of Vaccines Against Tuberculosis

Published on: July 28, 2023

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...